Cereno Scientific reports positive Phase I PK-bridging results for CS014, backs direct move to Phase IIb in PH-ILD
Bitget2026/09/25 08:15- Cereno Scientific reported positive topline results from a Phase I pharmacokinetic bridging study of HDAC inhibitor CS014.
- Results have been presented as topline data; fuller findings are slated for publication in 2027.
- Study supported the planned regulatory strategy to move CS014 directly into Phase IIb in PH-ILD, pending FDA review.
- Safety profile was consistent with prior Phase I experience, with mild adverse events and no serious events.
- IND submission is planned for Q4 2026; Phase IIb start is targeted for Q3 2027, subject to regulatory clearance.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
WikiLeaks Founder Julian Assange Welcomes Daughter With Terminator Quote
Bank of Japan minutes turn hawkish: Most members believe a rate hike is needed soon, with a 70% probability of a hike in December
Minutes from the Bank of Japan show that several members believe a rate hike is needed in the near term, with a roughly 70% probability of an increase in December. Core inflation has met the target for the first time in 30 years, and the current policy rate stands at 1.25%.
Former Chainlink Product Marketing Director Michael Robinson joins Monad Foundation
Crypto prices
More
